Method Optimization for the Quantification of the NAD

Method Optimization for the Quantification of the NAD (Nicotinamide Adenine Dinucleotide) Metabolome in Human Whole Blood, Plasma, and Urine, and Evaluation of Baseline Inter and Intra-subject Variability

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05561712

Enrollment

Registered

2022-09-30

Start date

2022-02-25

Completion date

2022-03-15

Last updated

2022-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAD

Keywords

NAD quantification in blood and urine

Brief summary

Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.

Detailed description

Whole blood from healthy participants will be collected to optimize analytical method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of the NAD metabolome in biological samples. Parameters such as collection volume and anti-coagulants will be investigated for optimal quantification. Moreover, inter- and intra-subject variability of NAD metabolite levels in whole blood will be evaluated. Plasma and urine will also collected for method development and variability measurements.

Interventions

OTHERLaboratory method validation

Test several sampling conditions

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy men and women (based on anamnesis), 2. Age between 18 and 55 years, 3. Body Mass Index (BMI) = weight (kg) / height (m)2 between 18.5 to 28 kg/m2.

Exclusion criteria

1. Pregnant or lactating women 2. Sick or with a strong cold 3. With vitamin B3 supplementations or under low carbohydrate of ketogenic diet 4. Under prescribed chronic medication, except contraceptive pill.

Design outcomes

Primary

Measure	Time frame	Description
Comparison of NAD metabolite concentrations in whole blood, collected with different tubes and anticoagulants.	through study completion, an average of 1 year	NAD metabolites in whole blood will be quantified by liquid chromatography-tandem

Secondary

Measure	Time frame	Description
Estimation of inter- and intra-subject variabilities of NAD metabolites in whole blood	through study completion, an average of 1 year	Descriptive estimates of the inter and intra subjects variances will be calculated with the standard formulas.
Validation of the method for a set of NAD metabolites in plasma and urine (including determination of Limit Of Detection-LOD, Limit Of Quantification- LOQ).	through study completion, an average of 1 year	NAD metabolites in urine and in blood will be quantified to enable to measure several validation parameters, such as intra and interday precision, LOD, LOQ, r2.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026